HOME >> MEDICINE >> NEWS
International study highlights underuse of reperfusion therapy for heart-attack patients

N.B. Please note that if you are outside North America the embargo time for Lancet Press Material is 0001 hours UK Time Friday 1st February 2002.

Up to a third of patients with a severe heart attack may not be receiving reperfusion therapy, despite the well-known benefits of this treatment strategy, conclude authors of an international study in this weeks issue of THE LANCET.

The benefits of reperfusion therapy- the use of fibrinolytic agents and/or coronary angioplasty to restore coronary artery bloodflow -for patients with acute coronary syndromes have been established, but there is variation in the type of reperfusion given and in decisions about which patients are eligible for such therapy. Kim Eagle from the University of Michigan Medical Center, USA, and colleagues assessed current practices in relation to reperfusion therapy in patients with a specific heart-attack profile called ST-segment-elevation myocardial infarction using data from the multinational, prospective Global Registry of Acute Coronary Events (GRACE). This registry includes data for patients with acute coronary syndromes from 94 hospitals in 14 countries.

The investigators assessed data of the first 9251 patients enrolled in GRACE; of these, 1763 presented within 12 hours of symptom onset with ST-segment-elevation myocardial infarction, 30% of whom did not receive reperfusion therapy. Elderly patients (75 years and older), those presenting without chest pain, and those with a history of diabetes, congestive heart failure, myocardial infarction, or coronary bypass surgery were less likely to receive reperfusion therapy. The rate of primary percutaneous coronary intervention was highest in the USA (17%) and lowest in Australia, New Zealand, and Canada (1%). The rate at sites with a catheterisation laboratory was 19%.

Kim Eagle comments: A substantial proportion of patients who are eligible for reperfusion therapy still do not receive this treatment.
'"/>

Contact: Richard Lane
richard.lane@lancet.com
44-20-7611-4076
Lancet
31-Jan-2002


Page: 1 2

Related medicine news :

1. International breast cancer prevention study launches in the United States and Canada
2. National Academies advisory: May 2 Symposium on International Science Policy
3. Awards & fellowships at the International & American Association for Dental Research General Session
4. Lectures, keynoters, symposia highlight International Dental Research meeting
5. Advances in Uterine Leiomyoma Research: 2nd NIH International Congress
6. International gathering of experts to share retinoblastoma breakthroughs
7. International trial of two microbicides begins
8. International gathering at UH examines top computer code
9. International trial finds benefits of breast MRI in women at high risk
10. International study provides culture-by-culture clues to family violence and abuse
11. St. Jude scientist wins International Society of Experimental Hematology award

Post Your Comments:
(Date:9/4/2015)... (PRWEB) , ... September 04, 2015 , ... According to ... been developed that changes color when subjected to an impact force that is great ... be implemented in helmets or other sporting equipment so that coaches or officials would ...
(Date:9/4/2015)... ... September 04, 2015 , ... According to an article published August ... Association presented data showing that it is safe for pregnant women to undergo local ... had undergone local anesthesia with a group that hadn’t, researchers were able to determine ...
(Date:9/4/2015)... ... September 04, 2015 , ... On ... has effectively doubled the size of its annual health tech innovation program. Now ... digital health startups to compete for cash and prizes to advance their technologies ...
(Date:9/4/2015)... , ... September 04, 2015 , ... With TransCel from ... mouse all within Final Cut Pro X. With TransCel users have full control over ... width, background color, speed method, frame color, inner color, text, and more. With TransCel ...
(Date:9/4/2015)... ... 2015 , ... Mile High Connects today releases “First and Last Mile Connections,” ... sidewalks, bike paths, and other vital supports severely limit access to public transportation for ... dollars to expand public transit, there’s very little support for safe and convenient access ...
Breaking Medicine News(10 mins):Health News:New Article on Head Injury Detection Technology Highlights Implications for Head Injury Detection in Sports, says The Law Offices of Burg & Brock 2Health News:Recent Study on Dental Care During Pregnancy Demonstrates How Preventative Dental Care Really is for Everyone, Says Medical Center Dental Care 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 2Health News:Insight Product Development Startup Competition on Track to Double Program Impact 3Health News:Pixel Film Studios Releases TransCel, a New FCPX Transition 2Health News:Missed Connections in Metro Denver Transit 2
(Date:9/4/2015)... , Sept. 4, 2015  Janssen Research & ... and Drug Administration (FDA) has accepted for Priority ... as a treatment for patients with multiple myeloma ... (PI) and an immunomodulatory agent (IMiD), or who ... therapy, including a PI and an IMiD. This ...
(Date:9/4/2015)... -- Fair Rate Funding, a lawsuit funding firm located in ... increase in lawsuit filings in connection with the blood thinning ... Philadelphia Court of Common Pleas has ... Louisiana multi---district litigation (MDL), located in ... Louisiana , the filings are also on the ...
(Date:9/4/2015)... HILL, N.C. , Sept. 4, 2015 /PRNewswire/ ... Liaisons (MSLs) and other Field-Based Medical Specialists (FBMS) ... key opinion leaders, and thought leaders in critical ... effectiveness of their field-based teams, companies are expanding ... order to align countries with corporate objectives and ...
Breaking Medicine Technology:U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 2U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 3U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 4U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 5U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 6U.S. FDA Grants Priority Review to Janssen for Daratumumab as a Treatment for Multiple Myeloma 7Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 2Xarelto Lawsuit Funding Firm, Fair Rate Funding Reports a Steady Rise in Xarelto Product Liability Lawsuit Filings 3New Study Presents Tactics and Insights on How to Effectively Globalize Medical Science Liaison Programs in the Pharmaceutical Industry 2
Cached News: